Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol) by E. S. Nesterova, S. K. Kravchenko, A. M. Kovrigina, E. G. Gemdzhian, L. V. Plastinina, Ya. K. Mangasarova, F. E. Babaeva, A. E. Misyurina, O. V. Margolin, A. U. Magomedova, V. I. Vorobiev, D. S. Maryin, E. A. Baryakh, Yu. Yu. Polyakov, P. A. Zeynalova, E. M. Volodicheva, N. N. Glonina, N. V. Minaeva, G. A. Davydova, V. G. Savchenko

“…Follicular lymphoma (FL) is the most common type of indolent lymphomas and accounts for 20–30 % of all non-Hodgkin’s lymphomas detected. High risk of recurrence and elderly patients make it difficult to choose induction therapy for FL. …”
Get full text